Oruka Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on Apr 25, 2024 and accepted by EDGAR at Apr 25, 2024, 16:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2024-01-01 to 2024-03-31 | $165.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 14,501,143 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-03-31 | $35.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $36.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $36.7m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $1.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $1.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $35.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-048329. Last ingested by Listed: Oct 26, 2026, 08:01 ET. Listed shows no prices and gives no investment advice.